ATS Medical Acquires Assets from EM Vascular.
MINNEAPOLIS, Dec. 4 /PRNewswire-FirstCall/ -- ATS Medical, Inc. a leader in providing innovative products and services focused on cardiac surgery today announced the acquisition of certain assets of EM Vascular, Inc. The transaction will be completed through an issuance of ATS Common Stock to EM Vascular, Inc. and subsequently...

Childhood, Youth Cancer Survival Factors Vary by Race, Follow-Up Care.
ORLANDO, Fla., Dec. 11 /PRNewswire/ -- Cancer is the leading cause of disease-related death among children in the U.S. The numbers of newly diagnosed patients across the major childhood cancers, such as leukemia and lymphoma, continue to escalate. But new research shows that mortality rates are improving and long-term...

New Options to Treat Chronic Myeloid Leukemia, Overcome Imatinib Resistance.
ORLANDO, Fla., Dec. 9 /PRNewswire/ -- The development of the targeted anticancer medicine imatinib has been a landmark event in the treatment of patients with chronic myeloid leukemia (CML), a cancer of the bone marrow. However, over time, the cancer can become resistant to this treatment, usually because of...

COLD-fX(TM)+* and the National Hockey League(R) Present the 'Mark Messier Leadership Award'.
Superior Leadership Qualities On and Off the Ice Recognized by Award NEW YORK, Nov. 14 /PRNewswire/ -- "We'll win tonight!" said Mark Messier before scoring a hat trick in game six of the 1994 National Hockey League(R) (NHL) Eastern Conference Championship to force a deciding game seven....

Gene Mutations Predict Treatment Outcomes in Patients With Leukemia [Abstract #4].
ORLANDO, Fla., Dec. 10 /PRNewswire/ -- Curing acute myeloid leukemia (AML), a rapidly progressing bone-marrow cancer, is possible, but only in about 20-30 percent of patients, depending on a number of prognostic factors. A team of German researchers who explored how treatment responses could vary based on the genetic...

Alternatives to Standard Chemotherapy Prolong Survival in Lymphoma, Leukemia Patients.
ORLANDO, Fla., Dec. 9 /PRNewswire/ -- Chemotherapy, the most common type of treatment for cancer patients, can cause troublesome side effects, such as nausea and vomiting, hair loss, fatigue, and life-threatening toxicities. An important area of progress has been the development of minimally toxic non- chemotherapy agents that add...

New Drug for Deep Vein Thrombosis Eases Treatment Regimen [Abstract #6].
ORLANDO, Fla., Dec. 10 /PRNewswire/ -- Deep vein thrombosis (DVT) occurs when a clot forms in one of the inner veins of the leg and can worsen into pulmonary embolism if the clot breaks away and travels to the lungs. Nearly 300,000 people in the United States die each...

Stem Cell Therapy Debate Lives On, but Research Continues to Find Effective Applications in Immune and Organ Function.
ORLANDO, Fla., Dec. 10 /PRNewswire/ -- While the debate over the ethical implications of stem cell research continues to embroil medical and political communities, researchers are successfully demonstrating the therapeutic value of human stem cells in a wide variety of diseases. Three studies being presented today at the 48th...

Semafore Granted Nearly One Million Dollars to Study SF1126 in Multiple Myeloma Patients.
- Second Significant Grant in Two Weeks for Clinical Trials of PI3 Kinase Inhibitor SF1126 - - SF1126 Pre-Clinical Myeloma Research Selected for Oral Presentation at ASH - INDIANAPOLIS, Dec. 5 /PRNewswire/ -- Semafore Pharmaceuticals, Inc. today announced receipt of a grant award from the...

New Award Honors Mentors for Their Role in Guiding the Careers of Junior Hematologists.
ORLANDO, Fla., Dec. 10 /PRNewswire/ -- The newly established Mentor Award, which highlights the value of mentorship in hematology, is being presented today to two awardees, Samuel E. Lux, MD, and Deane F. Mosher, MD, by the American Society of Hematology (ASH(TM)) during its 48th Annual Meeting. ...